AstraZeneca’s COVID-19 vaccine has achieved 70% efficacy in a late-phase analysis. The 70% figure is an average that masks variation in the performance of two dosing regimens, one of which was found to be 90% effective. The 70% efficacy figure is the average result for two regimens given to 11,636 people. Most subjects, 8,895, received the same dose for their first and second jabs. A smaller cohort, 2,741 subjects, got a half dose for the first jab followed by a full booster shot. Source: Fierce Biotech 23/11/2020